secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ginkgo Bioworks Holdings, Inc. (DNA)
CIK:        0001830214
Form:       8-K
Filed at:   2023-08-23T23:59:59+00:00
Accession:  0001193125-23-219091
Event type: other_material
Sentiment:  neutral
Materiality: 0.10
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ginkgo files updated pro forma financials for Zymergen acquisition; pro forma net loss $2.4B
--------------------------------------------------------------------------------

- Pro forma combined revenue $487.8M for FY 2022; Ginkgo standalone $477.7M, Zymergen $10.1M.
- Pro forma net loss attributable to Ginkgo stockholders $2.405B; diluted EPS loss $1.37.
- Adjustments include $8.1M net reduction in operating expenses from fair value and compensation changes.
- Weighted average shares outstanding increased to 1.76B from 1.68B due to Merger consideration shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1830214/000119312523219091/0001193125-23-219091-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1830214/000119312523219091/d506467d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-219091

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer